Skip to main content

Table 1 Clinicopathological variables associated with SRCs in LRC patients

From: Enhanced recovery after surgery nursing program, a protective factor for stoma-related complications in patients with low rectal cancer

Variables

SRCs

P-value

Yes

No

Number, n (%)

77 (26.7)

211 (73.3)

Age (year), n (%)

0.048*

 ≥ 65

47 (61.0)

101 (47.9)

 < 65

30 (39.0)

110 (52.1)

Gender, n (%)

0.114

 Male

48 (62.3)

152 (72.0)

 Female

29 (37.7)

59 (28.0)

BMI (kg/m2), n (%)

0.031*

 ≥ 24.5

31 (40.3)

57 (27.0)

 < 24.5

46 (59.7)

154 (73.0)

ASA grade, n (%)

0.668

 I/II

49 (63.6)

140 (66.4)

 III/IV

28 (36.4)

71 (33.6)

Charlson Comorbidity Index

3.2 ± 0.8

2.5 ± 0.6

 < 0.001

NRS 2002 score, n (%)

0.015*

 ≥ 3

17 (22.1)

23 (10.9)

 

 < 3

60 (77.9)

188 (89.1)

 

Active smoker, n (%)

1 0(13.0)

26 (12.3)

0.880

Heavy drinker, n (%)

8 (10.4)

22 (10.4)

0.993

Serum CEA (ng/mL), n (%)

0.686

 ≥ 5

36 (46.8)

93 (44.1)

 < 5

41 (53.2)

118 (55.9)

T stage, n (%)

0.409

 T1/2

23 (29.9)

74 (35.1)

 T3/4

54 (70.1)

13 7(64.9)

N stage, n (%)

0.163

 Negative

45 (58.4)

142 (67.3)

 Positive

32 (41.6)

69 (32.7)

TNM stage, n (%)

0.663

 I/II

46 (59.7)

120 (56.9)

 III

31 (40.3)

91 (43.1)

Pathologic differentiation, n (%)

0.936

 Well/moderate

62 (80.5)

169 (80.1)

 Poor/mucinous

15 (19.5)

42 (19.9)

Surgical approach, n (%)

0.371

 Laparoscopic

54 (70.1)

159 (75.4)

 Laparotomy

23 (29.9)

52 (24.6)

ERAS nursing program, n (%)

0.010*

 Yes

41 (53.2)

147 (69.7)

 No

36 (46.8)

64 (30.3)

Preoperative stoma localization, n (%)

10 (13.0)

51 (24.2)

0.040*

Operation time (min)

167.3 ± 37.4

155.9 ± 39.3

0.028*

Estimated blood loss (ml)

138.1 ± 50.5

146.5 ± 55.7

0.247

Height of stoma (mm)

10.7 ± 1.3

11.0 ± 1.2

0.067

Base area of stoma (cm2)

9.0 ± 1.1

8.7 ± 0.9

0.019*

  1. ERAS enhanced recovery after surgery, LRC low rectal cancer, SRCs stoma-related complications, BMI body mass index, ASA American Society of Anesthesiologists, NRS nutritional risk score, CEA carcinoembryonic antigen
  2. *P value < 0.05